^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD8835

    i
    Company:
    AstraZeneca
    Drug class:
    PI3K inhibitor, PI3Kα inhibitor, PI3Kδ inhibitor
    Related drugs:
    Apply
    Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours (NCT02260661)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    10/10/2016
    Initiation :
    11/01/2014
    Primary completion :
    07/01/2016
    Completion :
    07/01/2016
    HER-2 • ER • PIK3CA
    |
    ER positive • HER-2 negative • PIK3CA mutation
    |
    fulvestrant • AZD8835